The Role of Real-World Evidence in Shaping Pharma's Digital Future

This report delves into the pivotal role of real-world evidence (RWE) in the evolving pharmaceutical landscape, focusing on its increasing acceptance and application across the industry. It provides an in-depth analysis of current trends, highlighting the digitisation of healthcare data and the integration of artificial intelligence (AI) in RWE generation. Gain insights into the barriers that hinder RWE adoption, including data quality challenges and regional disparities in acceptance.

This report also explores how pharmaceutical companies are strategically investing in RWE to enhance drug development and market access. Additionally, it offers a forward-looking perspective on the future evolution of RWE, emphasising the potential for digital health technologies to transform patient care and regulatory decision making.

Key Questions Answered:

• 1. What are the current trends in the use and acceptance of real-world evidence (RWE)?
• 2. What barriers hinder the use and acceptance of RWE in the pharmaceutical industry?
• 3. How is the digitisation of healthcare data impacting RWE generation?
• 4. What role does artificial intelligence (AI) play in generating RWE?
• 5. How are pharmaceutical companies investing in RWE?
• 6. How will RWE generation evolve in the future?

Key Companies:

Partial List of Participating Experts:

• Head, Clinical Data Management, Flatiron Health, US
• Senior Market Access Manager, UCB, Australia
• Strategic Consultant, RWE, Belgium
• Managing Director, MedExcellence Solutions, Belgium
• RWE Digital Platforms Lead, multinational pharma company, US
• EU and Digital Data Transformation Lead, biopharma company, UK

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.